Nimodipine tested in a human model of cerebral ischaemia. Electroencephalographic and transcranial Doppler ultrasound investigations in normal subjects during standardized hyperventilation.

Abstract:

:The anti-ischaemic properties of nimodipine 30 mg and 60 mg t.i.d. for 4 days has been tested in a double-blind, placebo-controlled, cross-over study based on the use of hyperventilation to reduce flow velocity in cerebral arteries. Whether the anti-ischaemic properties were due to a vasodilatator action on cerebral blood vessels or to an anti-ischaemic effect on cerebral neurons was studied. There was a slight cardiovascular effect, without any significant change in the EEG at rest. During standardized hyperventilation, there was no difference in the reduction in the blood flow velocity in the nimodipine and placebo groups (namely 56%, 56% and 59%). Both doses of nimodipine, however, significantly attenuated the hyperventilation-induced increase in slow EEG activity in the 1.5-6.0 Hz range. It is concluded that the anti-ischaemic properties of nimodipine are due to an effect on the central nervous system rather than to an effect on cerebral blood flow.

journal_name

Eur J Clin Pharmacol

authors

Kraaier V,van Huffelen AC,Wieneke GH,Hesselink JM

doi

10.1007/BF00315133

subject

Has Abstract

pub_date

1991-01-01 00:00:00

pages

17-21

issue

1

eissn

0031-6970

issn

1432-1041

journal_volume

40

pub_type

临床试验,杂志文章
  • Pharmacokinetic interaction between indomethacin and diflunisal.

    abstract::The effect of treatment with diflunisal on the steady-state pharmacokinetics of indomethacin has been studied in 16 healthy volunteers. The steady-state plasma concentration and AUC of indomethacin were significantly increased two- to threefold during treatment with diflunisal and its total clearance and total volume ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00558077

    authors: Van Hecken A,Verbesselt R,Tjandra-Maga TB,De Schepper PJ

    更新日期:1989-01-01 00:00:00

  • Healthcare costs associated with elderly chronic pain patients in primary care.

    abstract:OBJECTIVE:This study aimed to estimate the total healthcare costs associated with elderly chronic pain (CP) patients, define cost-related factors in this population, and examine cost evolution over two years. METHOD:This is an ancillary study from the CP S.AGE subcohort, including non-institutionalized patients aged o...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-015-1871-6

    authors: Lazkani A,Delespierre T,Bauduceau B,Pasquier F,Bertin P,Berrut G,Corruble E,Doucet J,Falissard B,Forette F,Hanon O,Benattar-Zibi L,Piedvache C,Becquemont L

    更新日期:2015-08-01 00:00:00

  • Iloprost for prevention of contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure. Results of a randomized pilot study.

    abstract:OBJECTIVE:The prevention of contrast-mediated nephropathy (CMN), which accounts for considerable morbidity and mortality, remains a vexing problem. Contrast induced renal vasoconstriction is believed to play a pivotal role in the CMN mechanism. The aim of this pilot study was to examine the safety and efficacy of two d...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00228-006-0150-y

    authors: Spargias K,Adreanides E,Giamouzis G,Karagiannis S,Gouziouta A,Manginas A,Voudris V,Pavlides G,Cokkinos DV

    更新日期:2006-08-01 00:00:00

  • Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.

    abstract:OBJECTIVES:To compare plasma levodopa concentrations after repeated doses of levodopa/carbidopa/entacapone (LCE) and levodopa/carbidopa (LC). METHODS:Open-label, randomized, two-period, active-controlled, cross-over study with four dosing regimens: groups I and II (healthy volunteers and Parkinson's disease patients) ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00228-009-0622-y

    authors: Kuoppamäki M,Korpela K,Marttila R,Kaasinen V,Hartikainen P,Lyytinen J,Kaakkola S,Hänninen J,Löyttyniemi E,Kailajärvi M,Ruokoniemi P,Ellmén J

    更新日期:2009-05-01 00:00:00

  • Measuring human-error probabilities in drug preparation: a pilot simulation study.

    abstract:OBJECTIVES:Designing a safe medication process requires the ability to model its reliability using methods such as probabilistic risk assessment (PRA). However, lack of data, especially on human-error probabilities (HEPs), limits its use. To assess whether small-scale simulations could help generate HEP data, a pilot s...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-007-0319-z

    authors: Garnerin P,Pellet-Meier B,Chopard P,Perneger T,Bonnabry P

    更新日期:2007-08-01 00:00:00

  • Clinical Pharmacology in European health care-outcome of a questionnaire study in 31 countries.

    abstract:INTRODUCTION:In order to discover how well the discipline of clinical pharmacology (CP) has developed in Europe, a questionnaire survey was undertaken in 31 countries. METHODS:The senior delegate of each of the 31 countries on the Council of the European Association for Clinical Pharmacology and Therapeutics (EACPT) w...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-013-1519-3

    authors: Orme M,Sjöqvist F

    更新日期:2013-09-01 00:00:00

  • Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.

    abstract:OBJECTIVES:This study was conducted to examine a complex effect of ciprofibrate therapy in patients with atherogenic lipoprotein phenotype. METHODS:Effects of ciprofibrate were studied on HDL subpopulations, HDL ability to esterify cholesterol (FER(HDL)), susceptibility of LDL to oxidation as well as on in vivo oxidat...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s002280050537

    authors: Raslová K,Dobiásová M,Nagyová A,Fábry R,Rauchová H,Dusinská M

    更新日期:1998-11-01 00:00:00

  • Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patients-real-world data.

    abstract:PURPOSE:In the management of melanoma, BRAF inhibitors yield fast disease control; however, the duration of response does not last very long. Ipilimumab-an anti-CTLA4 antibody on the other hand-provides longer-lasting results of treatment but achieves less favorable responses. The aim of this study was to assess the ef...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-018-2590-6

    authors: Polkowska M,Ekk-Cierniakowski P,Czepielewska E,Kozłowska-Wojciechowska M

    更新日期:2019-03-01 00:00:00

  • The effects on ventilation of ketorolac in comparison with morphine.

    abstract::We have compared the effect on ventilation of ketorolac, an injectable non-steroidal analgesic, with that of morphine in a randomized, double-blind, cross-over study, using two doses of ketorolac (10 and 90 mg i.m.) and one of morphine (10 mg i.m.). The effect on ventilation was measured with a CO2 rebreathing techniq...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00558243

    authors: Bravo LJ,Mattie H,Spierdijk J,Bovill JG,Burm AG

    更新日期:1988-01-01 00:00:00

  • Lipid-lowering medication use and cancer-specific survival among endometrial or lung cancer patients: an Australian nationwide cohort study.

    abstract:PURPOSE:Inconsistent results of lipid-lowering medications (LLMs) on improved cancer survival need more investigations. We tested the hypothesis that adherence to the drug would be associated with a lower cancer-specific mortality in a homogeneous population who has ever used the drug. METHODS:Utilising data from the ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-020-03009-5

    authors: Feng JL,Qin X

    更新日期:2020-10-08 00:00:00

  • Genetic and environmental risk factors for oral anticoagulant overdose.

    abstract:BACKGROUND:Cytochrome P450 2C9 (CYP2C9) allelic variant carriers have been shown to experience hyper-responsiveness to small doses of oral anticoagulants (OAs) (warfarin or acenocoumarol) and a higher bleeding rate. OBJECTIVES:To determine the relative frequencies of different risk factors for OA overdose including di...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-002-0538-2

    authors: Verstuyft C,Robert A,Morin S,Loriot MA,Flahault A,Beaune P,Funck-Brentano C,Jaillon P,Becquemont L

    更新日期:2003-03-01 00:00:00

  • Influence of posture on pharmacokinetics.

    abstract:INTRODUCTION:Body position may influence physiological characteristics, such as perfusion, gastrointestinal function and plasma volume. These characteristics may interact with key factors determining the pharmacokinetics of drugs (dissolution, absorption, distribution, metabolism, excretion). OBJECTIVES:Based on a sys...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00228-008-0579-2

    authors: Queckenberg C,Fuhr U

    更新日期:2009-02-01 00:00:00

  • Comparative bioavailability of diclofenac hydroxyethylpyrrolidine vs diclofenac sodium in man.

    abstract::A phamacokinetic study in man has been made of a new dosage form of diclofenac hydroxyethylpyrrolidine (DIEP); soluble salt packed in sachets was compared with diclofenac sodium as enteric coated tablets. Oral DIEP 2 X 50 mg showed a significant difference in absorption kinetics (ka, lag time and tmax) as compared to ...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00265987

    authors: Maggi CA,Lualdi P,Mautone G

    更新日期:1990-01-01 00:00:00

  • The effect of acarbose on the pharmacokinetics of rosiglitazone.

    abstract:OBJECTIVES:To investigate whether treatment with acarbose alters the pharmacokinetics (PK) of coadministered rosiglitazone. METHODS:Sixteen healthy volunteers (24-59-years old) received a single 8-mg dose of rosiglitazone on day 1, followed by 7 days of repeat dosing with acarbose [100 mg three times daily (t.i.d.) wi...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s002280100275

    authors: Miller AK,Inglis AM,Culkin KT,Jorkasky DK,Freed MI

    更新日期:2001-05-01 00:00:00

  • A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.

    abstract:OBJECTIVE:To compare the efficacy and safety of repaglinide, a novel oral prandial glucose regulator, with that of glibenclamide, an oral hypoglycaemic agent, in the treatment of patients with type 2 diabetes. METHODS:This was a 14-week, double-blind, parallel-group trail in which a total of 195 type 2 diabetic patien...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/s002280050613

    authors: Landgraf R,Bilo HJ,Müller PG

    更新日期:1999-05-01 00:00:00

  • Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.

    abstract:OBJECTIVE:To assess the pharmacokinetics, safety and tolerability of escalating oral doses of GW420867X, a non-nucleoside reverse transcriptase inhibitor, was investigated in healthy male volunteers in a randomized, double-blind placebo-controlled study. METHODS:Study subjects were divided into four groups of 12 subje...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s002280000224

    authors: Moore KH,Cass LM,Dallow N,Hardman TC,Jones A,Boyce M,Prince WT

    更新日期:2001-01-01 00:00:00

  • Topical atorvastatin 1% for prevention of skin toxicity in patients receiving radiation therapy for breast cancer: a randomized, double-blind, placebo-controlled trial.

    abstract:BACKGROUND AND PURPOSE:The purpose of this randomized, placebo-controlled, double-blind study was to investigate the preventive effect of topical administration of atorvastatin (ATV) on the acute radiation-induced skin toxicity in patients with breast cancer. PATIENTS AND METHODS:Seventy breast cancer patients were ra...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00228-018-2570-x

    authors: Ghasemi A,Ghashghai Z,Akbari J,Yazdani-Charati J,Salehifar E,Hosseinimehr SJ

    更新日期:2019-02-01 00:00:00

  • Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis.

    abstract:BACKGROUND:Anti-tumor necrosis factor-alpha (TNF-α) agents have considerable advances in treating inflammatory bowel disease (IBD). These drugs carry possible risk of adverse symptoms, and no meta-analysis has examined this issue and the potential duration-response relationship. PURPOSE:The purpose of this study was t...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s00228-015-1877-0

    authors: Wang F,Lin X,Zhao Q,Li J

    更新日期:2015-08-01 00:00:00

  • Drug prescription in diabetic patients in Stockholm in 1992 and 1995--change over time.

    abstract:OBJECTIVE:To describe and compare the distribution of prescribed drugs in diabetic patients between 1992 and 1995. METHODS:Two cross-sectional surveys of a random selection of medical records of diabetic patients, from three community health centres (CHCs) in the Stockholm metropolitan area, were carried out. The age ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002280050285

    authors: Wändell PE,Brorsson B,Aberg H

    更新日期:1997-01-01 00:00:00

  • Haemodynamic effects of indenolol at rest and after a submaximal workload in essential hypertension.

    abstract::The effect of indenolol on heart rate and blood pressure at rest and after submaximal workload has been studied in 19 patients with established essential hypertension. A stepwise increase from moderate to submaximal exercise was chosen to mimic challenges normally occurring in daily life. After 4 weeks of once a day i...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00544058

    authors: Aiello C,Groothold G,Gualtieri S,Irace L,Marini IL,Perna B,Romano A

    更新日期:1985-01-01 00:00:00

  • Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males.

    abstract::The pharmacokinetics of ceftazidime have been investigated after single and multiple i.v. doses in 9 young healthy male volunteers and 15 elderly male patients with acute bacterial infections. All subjects had normal, age-correlated glomerular function. Distribution and elimination in young volunteers were unaffected ...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00614556

    authors: Ljungberg B,Nilsson-Ehle I

    更新日期:1988-01-01 00:00:00

  • Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives.

    abstract:OBJECTIVE:Contraception is recommended for female patients during ursodeoxycholic acid (UDCA) treatment for the potential teratogenic effect of this bile acid, and the aim of our study was to determine whether this treatment affects the bioavailability of ethinylestradiol (EE2). METHODS:In this double-blind, randomise...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s00228-004-0796-2

    authors: Baisini O,Benini F,Petraglia F,Kuhnz W,Scalia S,Marschall HU,Brunetti G,Tauschel HD,Lanzini A

    更新日期:2004-09-01 00:00:00

  • Pharmacokinetics and protein binding of cefazolin in morbidly obese patients.

    abstract:PURPOSE:The aim of this study was to assess the pharmacokinetics and protein binding of cefazolin in morbidly obese patients undergoing bariatric surgery, to study the influence of bodyweight measures and age on pharmacokinetic parameters and to evaluate unbound cefazolin concentrations over time in this population. M...

    journal_title:European journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00228-011-1048-x

    authors: van Kralingen S,Taks M,Diepstraten J,van de Garde EM,van Dongen EP,Wiezer MJ,van Ramshorst B,Vlaminckx B,Deneer VH,Knibbe CA

    更新日期:2011-10-01 00:00:00

  • Drug-induced immune thrombocytopaenia: results from the Berlin Case-Control Surveillance Study.

    abstract:PURPOSE:Drug-induced immune thrombocytopaenia is a rare, serious condition that can be triggered by numerous medications. To characterize the spectrum of drugs associated with immune thrombocytopaenia (ITP) in the Berlin Case-Control Surveillance Study (FAKOS). METHODS:Adult hospitalized patients with new onset idiopa...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00228-011-1184-3

    authors: Garbe E,Andersohn F,Bronder E,Salama A,Klimpel A,Thomae M,Schrezenmeier H,Hildebrandt M,Späth-Schwalbe E,Grüneisen A,Meyer O,Kurtal H

    更新日期:2012-05-01 00:00:00

  • Pharmacokinetics of TZU-0460, a new H2-receptor antagonist, in patients with impaired renal function.

    abstract::We have studied pharmacokinetics of a new H2-receptor antagonist, TZU-0460, in patients with varying degrees of renal impairment. The apparent volume of distribution at steady-state was 1.70 l/kg, and the plasma protein binding of TZU-0460 or its active metabolite, desacetyl TZU-0460 was less than 10% in normal subjec...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00608220

    authors: Takabatake T,Ohta H,Yamamoto Y,Ishida Y,Hara H,Nakamura S,Ushiogi Y,Satoh S,Hattori N

    更新日期:1986-01-01 00:00:00

  • An analysis of the clinical development of drugs in Norway for the year 2000: the completion of research and publication of results.

    abstract:OBJECTIVE:In Norway, very little data are available on the relation between the total number of research projects on the clinical development of drugs that have been started, the number of these projects in which the research phase has been completed and the number of projects for which results have been published. The...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-008-0601-8

    authors: Hole OP,Nitter-Hauge S,Cederkvist HR,Winther FO

    更新日期:2009-03-01 00:00:00

  • Trends of prescribing patterns for the secondary prevention of myocardial infarction over a 13-year period.

    abstract:OBJECTIVE:The efficacy of beta-adrenergic blocking agents and acetylsalicylic acid in the secondary prevention of myocardial infarction has been well recognized since the beginning of the 1980s. In a previous paper, however, we reported a lower than expected use of these drugs during the period 1982 1988. In 1989 the r...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002280050446

    authors: Martínez M,Agustí A,Arnau JM,Vidal X,Laporte JR

    更新日期:1998-05-01 00:00:00

  • Relationship between recommended chronic heart failure treatments and mortality over 8 years in real-world conditions: a pharmacoepidemiological study.

    abstract:PURPOSE:We previously reported that chronic heart failure (CHF) treatments reduce the duration of hospitalisation, even in elderly patients. The present study aimed to determine whether CHF treatment also provides long-term benefits in terms of reduced mortality at 8 years. METHODS:A cohort of 281 patients who were ad...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00228-012-1400-9

    authors: Maison P,Desamericq G,Hemery F,Elie N,Del'volgo A,Dubois-Randé JL,Hittinger L,Macquin-Mavier I

    更新日期:2013-04-01 00:00:00

  • Comparative pharmacokinetic study of adriamycin and 4'epi-adriamycin after their simultaneous intravenous administration.

    abstract::The plasma pharmacokinetics of adriamycin and 4'epi-adriamycin have been studied in 6 patients with ovarian carcinoma after simultaneous intravenous administration of equal amounts of the two anthracyclines. A highly selective liquid chromatographic analytical method permitted quantification of plasma concentrations o...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00542426

    authors: Eksborg S,Stendahl U,Lönroth U

    更新日期:1986-01-01 00:00:00

  • Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.

    abstract:OBJECTIVE:The aim of this investigation was to clarify the stereoselective properties in lansoprazole metabolism by monitoring the metabolic consumption for each enantiomer and the formation of the main metabolites, lansoprazole sulfone and 5-hydroxylansoprazole, in the presence of human liver microsomal enzymes. METH...

    journal_title:European journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002280100374

    authors: Katsuki H,Hamada A,Nakamura C,Arimori K,Nakano M

    更新日期:2001-12-01 00:00:00